JAK2 and essential thrombocythemia: After JAK2 mutations, CALR mutations are the second most common driver mutations in ET and PMF, being reported primarily in the context of JAK2 and MPL wild-type PMF (25%–35%) and ET (20%–25%) (Rumi et al., 2014b; Tefferi et al., 2014).